3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
5
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Stomach Neoplasms
11
Carcinoma, Hepatocellular
7
Esophageal Neoplasms
6
Rectal Neoplasms
5
Colonic Neoplasms
5
Neoplasms
4
Lymphatic Metastasis
3
Colorectal Neoplasms
3
Peritoneal Neoplasms
2
Vulvar Neoplasms
1
Uterine Cervical Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Inflammatory Bowel Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Diseases
1
Gastric Adenocarcinoma
1
Endometrial Neoplasms
1
Diverticular Diseases
1
Colorectal Cancer Metastatic
1
Chylothorax
1
Interventions
pembrolizumab
35
Nivolumab
13
Cyclophosphamide
11
fludarabine
9
aldesleukin
9
atezolizumab
7
Magnetic Resonance Spectroscopy
7
Carboplatin
7
Specimen Handling
6
Ipilimumab
6
Early Intervention, Educational
6
Cisplatin
6
Trastuzumab
5
Paclitaxel
5
Methods
5
Biopsy
5
Bevacizumab
5
durvalumab
4
Vaccines
4
Surveys and Questionnaires
4
Radiotherapy
4
Papillomavirus Vaccines
4
Interleukin-2
4
Docetaxel
4
tisotumab vedotin
3
spartalizumab
3
fludarabine phosphate
3
cemiplimab
3
aflibercept
3
Tomography, X-Ray Computed
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Indocyanine Green
×
Gastrointestinal
×
Clear all
NCT02997553
2023-01-09
GASVERT
Institut de Cancérologie de Lorraine
Phase 3
Completed
744 enrolled